MCID: ANL011
MIFTS: 40

Anal Canal Carcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases

Aliases & Classifications for Anal Canal Carcinoma

MalaCards integrated aliases for Anal Canal Carcinoma:

Name: Anal Canal Carcinoma 58 12 13 45 15
Anal Canal Cancer 12 15
Anal Canal and Perianal Gland Carcinoma 12
Cancer of the Anal Canal 38
Carcinoma of Anal Canal 74

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
anal canal carcinoma:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:0050688 DOID:6126
OMIM 58 105580
KEGG 38 H00044
MeSH 45 C563020
NCIt 51 C7489
ICD10 34 C21.1
MedGen 43 C0563211
SNOMED-CT via HPO 70 263681008
UMLS 74 C0563211

Summaries for Anal Canal Carcinoma

Disease Ontology : 12 An anal canal cancer that derives from epithelial cells.

MalaCards based summary : Anal Canal Carcinoma, also known as anal canal cancer, is related to anal carcinoma in situ and anal canal adenocarcinoma. An important gene associated with Anal Canal Carcinoma is ANC (Anal Canal Carcinoma), and among its related pathways/superpathways is Viral carcinogenesis. The drugs Fluorouracil and nivolumab have been mentioned in the context of this disorder. Affiliated tissues include liver, prostate and endothelial, and related phenotypes are anal canal squamous carcinoma and Reduced mammosphere formation

Description from OMIM: 105580

Related Diseases for Anal Canal Carcinoma

Diseases related to Anal Canal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Related Disease Score Top Affiliating Genes
1 anal carcinoma in situ 11.5
2 anal canal adenocarcinoma 11.2
3 anal canal squamous cell carcinoma 11.2
4 maternal uniparental disomy of chromosome 22 10.3
5 cervical intraepithelial neoplasia 10.1 NME1 CDKN2A
6 inverted transitional papilloma 10.1 KRT7 CDKN2A
7 papilloma 10.1 KRT7 CDKN2A
8 bladder carcinoma in situ 10.1 KRT7 CDKN2A
9 skin melanoma 10.1 NME1 CDKN2A
10 endocervical carcinoma 10.1 KRT7 CDKN2A
11 bile duct adenoma 10.1 KRT7 CDKN2A
12 adenoid basal cell carcinoma 10.1 KRT7 CDKN2A
13 vulval paget's disease 10.1 KRT7 CDKN2A
14 nasal cavity cancer 10.1 KRT7 CDKN2A
15 nasal cavity adenocarcinoma 10.1 KRT7 CDKN2A
16 vulvar disease 10.1 KRT7 CDKN2A
17 vulva adenocarcinoma 10.1 KRT7 CDKN2A
18 glycogen-rich clear cell breast carcinoma 10.1 KRT7 CDKN2A
19 well-differentiated liposarcoma 10.1 KRT7 CDKN2A
20 mucinous bronchioloalveolar adenocarcinoma 10.1 KRT7 CDKN2A
21 laryngeal squamous cell carcinoma 10.0 NME1 CDKN2A
22 nasal cavity squamous cell carcinoma 10.0 KRT7 CDKN2A
23 endocervical adenocarcinoma 10.0 KRT7 CDKN2A
24 cervical adenocarcinoma 10.0 CDKN2A KRT7
25 cervical adenosquamous carcinoma 10.0 KRT7 CDKN2A
26 basaloid squamous cell carcinoma 10.0 KRT7 CDKN2A
27 necrotizing sialometaplasia 10.0 KRT7 CDKN2A
28 adenocarcinoma in situ 10.0 KRT7 CDKN2A
29 tonsil cancer 10.0 KRT7 CDKN2A
30 vulva cancer 10.0 KRT7 CDKN2A
31 mucinous adenocarcinoma 10.0 KRT7 CDKN2A
32 pancreatic ductal carcinoma 10.0 KRT7 CDKN2A
33 inverted papilloma 10.0 KRT7 CDKN2A
34 hypopharynx cancer 10.0 NME1 CD6
35 pharynx cancer 10.0 CDKN2A CD6
36 small cell carcinoma 10.0 KRT7 CDKN2A
37 systemic lupus erythematosus 9.9
38 prostate cancer 9.9
39 prostate cancer, hereditary, 8 9.9
40 prostate cancer, hereditary, 6 9.9
41 squamous cell carcinoma 9.9
42 mammary paget's disease 9.9
43 lupus erythematosus 9.9
44 suppression of tumorigenicity 12 9.9
45 leukemia 9.9
46 adenocarcinoma 9.9
47 cell type benign neoplasm 9.9 KRT7 CDKN2A
48 tongue disease 9.9 CDKN2A CD6
49 chordoma 9.9 KRT7 CDKN2A
50 rectal disease 9.9 CDKN2A CD6

Graphical network of the top 20 diseases related to Anal Canal Carcinoma:



Diseases related to Anal Canal Carcinoma

Symptoms & Phenotypes for Anal Canal Carcinoma

Human phenotypes related to Anal Canal Carcinoma:

33
# Description HPO Frequency HPO Source Accession
1 anal canal squamous carcinoma 33 HP:0006763

Symptoms via clinical synopsis from OMIM:

58
Oncology:
anal canal squamous carcinoma

Clinical features from OMIM:

105580

GenomeRNAi Phenotypes related to Anal Canal Carcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 8.92 CD6 KRT7 NME1 RAN

Drugs & Therapeutics for Anal Canal Carcinoma

Drugs for Anal Canal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 2 51-21-8 3385
2
nivolumab Approved Phase 2,Phase 1 946414-94-4
3
Ipilimumab Approved Phase 2,Phase 1 477202-00-9
4
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
5
Cisplatin Approved Phase 2 15663-27-1 441203 84093 2767
6
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
7
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
8 Daratumumab Approved Phase 1, Phase 2 945721-28-8
9
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
10
Carboplatin Approved Phase 2 41575-94-4 38904 10339178 498142
11
Durvalumab Approved, Investigational Phase 2 1428935-60-7
12
Nimotuzumab Investigational Phase 2 780758-10-3, 828933-61-3
13 Mitoguazone Investigational Phase 2 459-86-9
14 Anti-Bacterial Agents Phase 2
15 Mitomycins Phase 2
16 Nucleic Acid Synthesis Inhibitors Phase 2
17 Alkylating Agents Phase 2
18 Antibiotics, Antitubercular Phase 2
19 Antibodies Phase 2,Phase 1
20 Antibodies, Monoclonal Phase 2,Phase 1
21 Antineoplastic Agents, Immunological Phase 2,Phase 1
22 Immunoglobulins Phase 2,Phase 1
23 Antimetabolites Phase 2
24 Immunosuppressive Agents Phase 2
25 Antimetabolites, Antineoplastic Phase 2
26 Immunologic Factors Phase 2,Phase 1
27 Antimitotic Agents Phase 2
28 taxane Phase 2
29 Liver Extracts Phase 2
30 Albumin-Bound Paclitaxel Phase 2
31 Antineoplastic Agents, Phytogenic Phase 2
32 Vaccines Phase 2
33 Interleukin-12 Phase 2
34 Adjuvants, Immunologic Phase 2
35 Immunoglobulin G Phase 2
36 Angiogenesis Modulating Agents Phase 2
37 Angiogenesis Inhibitors Phase 2

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 A Phase II Study to Assess Acute Toxicity and Quality of Life of Patients With Carcinoma of the Anal Canal Receiving Chemotherapy and Radiation Using Helical Tomotherapy Unknown status NCT00754078 Phase 2
2 Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life Recruiting NCT02701088 Phase 2 5Fluorouracile and Mitomycin-C
3 Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer Recruiting NCT02314169 Phase 2
4 Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers Terminated NCT01382745 Phase 2 Nimotuzumab
5 A Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal. Completed NCT01941966 Phase 2 Capecitabine;Mitomycins
6 Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma Active, not recruiting NCT02402842 Phase 2 Docetaxel, Cisplatin and 5-Fluorouracil
7 Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal Terminated NCT01843452 Phase 2 MITOMYCIN;CAPECITABINE
8 A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy Recruiting NCT03597295 Phase 2 INCMGA00012
9 Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection Recruiting NCT02437851 Phase 2
10 An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors Recruiting NCT02488759 Phase 1, Phase 2 Nivolumab;Ipilimumab;Relatlimab;Daratumumab
11 Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases Recruiting NCT02185443 Phase 2
12 Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers Recruiting NCT03403465 Phase 2
13 Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer Active, not recruiting NCT02560298 Phase 2 Capecitabine;Carboplatin;Cisplatin;Fluorouracil;Paclitaxel
14 Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer Recruiting NCT03233711 Phase 2
15 DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Participants With Recurrent or Metastatic Human Papillomavirus Associated Cancers Recruiting NCT03439085 Phase 2
16 LET-IMPT and Standard Chemotherapy in Treating Patients With Newly Diagnosed Stage I-III Anal Canal Squamous Cell Cancer Recruiting NCT03690921 Phase 2 Cisplatin;Fluorouracil
17 Interstitial Brachytherapy Boost for Treatment of Anal Canal Cancers, Comparison of Two Dose Rates Completed NCT03465501
18 Medico-economic Evaluation Comparing Intensity-Modulated Radiation Therapy (IMRT) Performed by Helical Tomotherapy and Dynamic Arc Therapy in Prostate, Cervical and Anal Canal Cancers Active, not recruiting NCT01325961 Not Applicable
19 "Cross" Closure for Reconstructing the Perineal Wound of Abdominoperineal Resection Not yet recruiting NCT03731754 Not Applicable
20 Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal Recruiting NCT01845779 Not Applicable DCF regimen
21 Individual Following in Anal Cancer With PET/CT Recruiting NCT02697084
22 Chemoradiation and Endothelial Progenitor Cells in Colorectal Cancer Completed NCT00325871

Search NIH Clinical Center for Anal Canal Carcinoma

Cochrane evidence based reviews: anal canal carcinoma

Genetic Tests for Anal Canal Carcinoma

Anatomical Context for Anal Canal Carcinoma

MalaCards organs/tissues related to Anal Canal Carcinoma:

42
Liver, Prostate, Endothelial, Skin

Publications for Anal Canal Carcinoma

Articles related to Anal Canal Carcinoma:

(show top 50) (show all 113)
# Title Authors Year
1
Long-term results of chemoradiation plus pulsed-dose-rate brachytherapy boost in anal canal carcinoma: A mono-institutional retrospective analysis. ( 30911306 )
2019
2
Prognostic significance of inflammatory-related parameters in patients with anal canal cancer. ( 30617412 )
2019
3
Role of pelvic chemoradiation therapy in patients with initially metastatic anal canal cancer: A National Cancer Data Base review. ( 30825391 )
2019
4
Association of Interim FDG-PET Imaging During Chemoradiation for Squamous Anal Canal Carcinoma With Recurrence. ( 29891206 )
2018
5
Management of locally advanced anal canal carcinoma with intensity-modulated radiotherapy and concurrent chemotherapy. ( 30128811 )
2018
6
Prognostic factors of colostomy free survival in patients presenting with locally advanced anal canal carcinoma: A pooled analysis of two prospective trials (KANAL 2 and ACCORD 03). ( 30172453 )
2018
7
Synchronous anal canal carcinoma in a heterosexual couple. ( 30200930 )
2018
8
Clinical and Economic Evaluation of Treatment Strategies for T1N0 Anal Canal Cancer. ( 27755059 )
2018
9
Prognostic and Predictive Clinicopathologic Factors of Squamous Anal Canal Cancer in HIV-Positive and HIV-Negative Patients: Does HAART Influence Outcomes? ( 28948325 )
2018
10
Definitive chemoradiotherapy for anal canal cancer: single-center experience. ( 29992389 )
2018
11
A Definitive IMRT-SIB with Concomitant Chemotherapy for Synchronous Locally Advanced Anal Canal Cancer and Prostate Cancer. ( 30034895 )
2018
12
Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET/CT in anal canal cancer. ( 27503193 )
2017
13
Diagnosis and Diagnostic Imaging of Anal Canal Cancer. ( 27889036 )
2017
14
Epidemiology of Anal Canal Cancer. ( 27889039 )
2017
15
Results of Surgical Salvage Treatment for Anal Canal Cancer: A Retrospective Analysis with Overview of the Literature. ( 28099957 )
2017
16
Predictors of Nonadherence to NCCN Guideline Recommendations for the Management of Stage I Anal Canal Cancer. ( 28275036 )
2017
17
Elevated risk of human papillomavirus-related second cancers in survivors of anal canal cancer. ( 28608917 )
2017
18
PET imaging in anal canal cancer: a systematic review and meta-analysis. ( 28972796 )
2017
19
Anal Canal Carcinoma in a Child With Disorders of Sex Development. ( 27037640 )
2016
20
Proteomic signatures reveal a dualistic and clinically relevant classification of anal canal carcinoma. ( 27976366 )
2016
21
Shifting paradigm in the management of anal canal carcinoma. ( 25432583 )
2015
22
Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities. ( 25903798 )
2015
23
Locally advanced anal canal carcinoma: is the addition of cetuximab the answer? ( 25976929 )
2015
24
Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. ( 24243447 )
2014
25
Management of persistent anal canal carcinoma after combined-modality therapy: a clinical review. ( 24472223 )
2014
26
Reply to phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. ( 24243421 )
2014
27
Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. ( 23674135 )
2013
28
Benefit of MRI scanning in the pretreatment assessment of anal canal carcinoma. ( 24674573 )
2013
29
Changing patterns of anal canal carcinoma in the United States. ( 23509304 )
2013
30
Light microscopic observation on phagocytosis of Candida spp. blastospores by Trichomonas vaginalis in a patient with anal canal carcinoma. ( 21395883 )
2012
31
Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. ( 22529257 )
2012
32
Chemotherapy in the treatment of anal canal carcinoma. ( 22658644 )
2012
33
Endobronchial metastases of anal canal carcinoma. ( 22055765 )
2012
34
Anal canal carcinoma treatment results: the experience of a single institution. ( 21403412 )
2011
35
The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series. ( 21772841 )
2011
36
Mitomycin-C- or cisplatin-based chemoradiotherapy for anal canal carcinoma: long-term results. ( 20472349 )
2011
37
Results of salvage abdominoperineal resection after failed chemoradiation therapy for epidermoid anal canal carcinoma: Retrospective analysis at a single institution. ( 22331724 )
2011
38
Twenty-year experience in the management of squamous cell anal canal carcinoma with interstitial brachytherapy. ( 21775274 )
2011
39
Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma. ( 20492729 )
2010
40
Post burn Marjolin's ulcer in the natal cleft mimicking anal canal carcinoma: a rare site. ( 21160444 )
2010
41
Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. ( 19399614 )
2010
42
Conformal external beam radiotherapy in the treatment of anal canal carcinoma: a retrospective study of a genital organ sparing technique. ( 19695047 )
2009
43
Size does matter: can we reduce the radiotherapy field size for selected cases of anal canal cancer undergoing chemoradiation? ( 19282157 )
2009
44
Current management of anal canal cancer. ( 19336010 )
2009
45
Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). ( 18490648 )
2008
46
Radiotherapy and chemotherapy in the conservative treatment of anal canal carcinoma. ( 18505075 )
2008
47
Radiochemotherapy of locally advanced anal canal carcinoma: prospective assessment of early impact on the quality of life (randomized trial ACCORD 03). ( 18191265 )
2008
48
Chemotherapy and radiotherapy for anal canal carcinoma. ( 18812528 )
2008
49
Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. ( 18005443 )
2007
50
External beam radiotherapy plus brachytherapy boost in treatment of anal canal carcinoma. ( 17988027 )
2007

Variations for Anal Canal Carcinoma

Expression for Anal Canal Carcinoma

Search GEO for disease gene expression data for Anal Canal Carcinoma.

Pathways for Anal Canal Carcinoma

Pathways related to Anal Canal Carcinoma according to KEGG:

38
# Name Kegg Source Accession
1 Viral carcinogenesis hsa05203

GO Terms for Anal Canal Carcinoma

Biological processes related to Anal Canal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.43 CDKN2A NME1 TENM1
2 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 8.96 CD6 TENM1
3 hippocampus development GO:0021766 8.85 NME1
4 DNA metabolic process GO:0006259 8.62 NME1 RAN

Sources for Anal Canal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....